Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biosense Webster, Inc.
This study is purposed to measure "real world" acute procedural outcomes (procedural efficiency and acute safety) associated with use of the CARTO® 3 System and real time intracardiac ultrasound in a clinical setting in subjects with drug refractory recurrent symptomatic paroxysmal AF.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Drug refractory, recurrent symptomatic paroxysmal AF
Age 18 years or older
Patients able and willing to provide written informed consent to participate in the study and comply with study requirements
You may not be if
Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
Previous ablation for atrial fibrillation
AF episodes that last longer than 30 days
Uncontrolled heart failure, or NYHA Class III or IV heart failure
Documented intra-atrial thrombus or other abnormality on pre-ablation imaging
Contraindication to anticoagulation
Stroke, cardiac surgery, unstable angina, myocardial infarction or percutaneous coronary intervention within the past 3 months
Awaiting cardiac transplantation
Heart disease for which corrective surgery is anticipated within 6 months
Enrollment in other investigational drug or device study
Subjects unwilling to comply with protocol or follow-up requirements
Patients who are pregnant
Clareo Health | CARTO® 3 System and Real Time Intracardiac Ultrasound
